KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Total Current Liabilities (2019 - 2026)

GoodRx Holdings' Total Current Liabilities history spans 7 years, with the latest figure at $246.0 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 98.54% to $246.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $246.0 million, a 98.54% increase, with the full-year FY2025 number at $246.0 million, up 98.54% from a year prior.
  • Total Current Liabilities hit $246.0 million in Q4 2025 for GoodRx Holdings, up from $181.9 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for GDRX hit a ceiling of $246.0 million in Q4 2025 and a floor of $59.4 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $104.7 million across 5 years, with a median of $93.7 million in 2022.
  • The widest YoY moves for Total Current Liabilities: up 98.54% in 2025, down 11.28% in 2025.
  • Tracing GDRX's Total Current Liabilities over 5 years: stood at $81.1 million in 2021, then decreased by 5.91% to $76.3 million in 2022, then surged by 60.59% to $122.6 million in 2023, then increased by 1.1% to $123.9 million in 2024, then skyrocketed by 98.54% to $246.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for GDRX at $246.0 million in Q4 2025, $181.9 million in Q3 2025, and $130.9 million in Q2 2025.